Pancreatic/Thyroid/Other Endocrine Cancers Archives - MPR

Pancreatic/Thyroid/Other Endocrine Cancers

Lynparza Gains Pancreatic Cancer Indication

AstraZeneca and Merck announced that the Food and Drug Administration (FDA) has approved Lynparza (olaparib) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. The FDA’s Oncologic Drugs Advisory Committee…